{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-033541","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.534512+00:00","generated_at":"2026-05-17T09:07:37.618291+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction","bullets":["Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)","Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies","Over 90% of patients from CORE/CORE2 enrolled in open-label extension study","Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-033541","json":"https://secwatch.observer/filing/0001140361-25-033541.json","markdown":"https://secwatch.observer/filing/0001140361-25-033541.md","text":"https://secwatch.observer/filing/0001140361-25-033541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/0001140361-25-033541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/ef20054942_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T09:07:37.618291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}